(Q33769335)

English

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

2

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

8

object named as

Stefan Faderl

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

5

object named as

Zeev Estrov

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Srdan Verstovsek

6

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jorge Eduardo Cortes

11

object named as

Jorge Cortes

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

7

object named as

Susan O'Brien

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

3

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1

object named as

Elias Jabbour

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Guillermo Garcia-Manero

4

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Deborah A Thomas

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

John J Wright

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

19 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

117

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1236-1244

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

New agents in acute myeloid leukemia and other myeloid disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

Treatment of relapsed and refractory acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4061136

4 July 2018

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25575

21 January 2018

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25575

21 January 2018

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25575

21 January 2018

Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25575

21 January 2018

A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25575

21 January 2018

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25575

21 January 2018

Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25575

21 January 2018

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25575

21 January 2018

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25575

21 January 2018

Identifiers

10.1002/CNCR.25575

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33769335&oldid=1534082655"